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Chronic lymphocytic leukaemia (CLL), non-Hodgkin￿s lymphoma
CLL-like (NHL-A) and Waldenstr￿m￿s macroglobulinaemia (M)
are incurable indolent B-cell lymphoproliferative disorders.
Differences in response rate to various agents may be seen
between these three distinct pathological entities and remissions
can be achieved with single drug or combined chemotherapy.
However, median survival reaches only 5—10 years (Lister et al,
1978; Rosenberg, 1985). The majority of patients present with
advanced disease, and therapeutic strategies may vary from
watchful waiting to immediate aggressive therapies (Young et al,
1988). Standard treatment is based on an alkylating agent such as
cyclophosphamide or chlorambucil, with responses observed in
two-thirds of untreated patients. At relapse or in resistant disease,
combination regimens may induce some durable responses
(Velasquez et al, 1988).
Among agents recently introduced in clinical practice, purine
analogues such as cladribine have shown useful activity in both
previously treated and untreated patients with indolent lymphoid
malignancies (Piro et al, 1990; Beutler, 1992; Kay et al, 1992;
Saven et al, 1992; Dimopoulos et al, 1993; Hickish et al, 1993;
Juliusson and Liliemark, 1993, 1996; Hoffman et al, 1994; Saven
and Piro, 1994; Delannoy et al, 1995; Saven et al, 1995; Betticher
et al, 1996). Lack of cross-resistance between cladribine and
fludarabine, another purine analogue, has also been reported
but not confirmed (Juliusson et al, 1992; O￿Brien et al, 1994).
Inhibition of DNA repair together with the role of the enzymes
5¢-nucleotidase and deoxycytidine kinase has been well underlined
in determining the activity of the purine analogues (Danhauser et
al, 1986; Kawasaki et al, 1993; Robertson et al, 1993). In addition,
synergy with other agents, such as the alkylating agents, is
expected from in vitro studies and has already been demonstrated
in the clinics with fludarabine combined with cyclophosphamide
(Hosek et al, 1991; O￿Brien et al, 1996).
Cladribine administered as a single agent for 7 days to patients
with indolent lymphoid malignancies resulted in dose-dependent
infections and cumulative myelotoxicity limited the dose
(Betticher et al, 1993, 1994). The same range of complications has
been shown with cladribine given in combination with either
chlorambucil or mitoxantrone to patients with indolent lymphoid
malignancies (Tefferi et al, 1994; Saven et al, 1996). Early enthu-
siasm for the association of cladribine with other active cytotoxic
agents may thus have been hampered by such adverse experiences.
Nevertheless, the rationale still persists for the inclusion of
cladribine in the therapeutic armamentarium. Based on our
previous data with single-agent cladribine, we have administered
this agent in combination with cyclophosphamide and prednisone,
the present local standard, to assess the toxicity profile of this
combination (CCP) and its activity. Cladribine is registered to be
given through a continuous intravenous infusion but this makes
the treatment difficult in the outpatient and hospitalization may
be necessary. In addition, the bioavailability of subcutaneous
cladribine has been shown to be similar to that of the standard
intravenous infusion (Liliemark et al, 1992) and we thus selected
the subcutaneous route. Oral cladribine could have been an attrac-
tive alternative but early results suggested that this route is associ-
ated with high and unpredictable toxicity (Juliusson et al, 1996).
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Summary The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid
malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin’s lymphoma (NHL) and
three macroglobulinaemia (M))] received cladribine 0.1 mg kg–1 per day as a subcutaneous bolus injection on days 1–3 (up to 5 injections)
with intravenous cyclophosphamide 500 mg m–2 on day 1 and oral prednisone 40 mg m–2 on days 1–5 at 4-weekly intervals up to a maximum
of six courses. A total of 80 courses were given. Overall response rate was 88%, with four patients achieving a complete clinical and
haematological response and 12 achieving a partial response. Neutropenia WHO grade 4 in two patients and WHO grade 3 infection in one
patient were the limiting toxicities on treatment. During the follow-up, WHO grade ³3 haematological complications occurred in five patients
and WHO grade ³3 non-haematological complications in five patients. There were no treatment-related deaths. This study demonstrates the
feasibility of the cladribine/cyclophosphamide/prednisone (CCP) combination that appears highly active and safe in the management of
indolent lymphoid malignancies.
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Patients (Table 1)
Between October 1993 and September 1995, patients presenting
with CLL Binet stage B—C, IWF NHL-A or M stage III—IV were
recruited. Only those not previously treated with purine analogues,
a WHO performance †2 and a negative HIV serology could enter
the study. Diagnosis was established by both cytological and
immunological studies of lymph nodes, blood smears and bone
marrow aspirate and biopsy. The study was approved by the ethics
committee of the department of medicine of Geneva University
Hospitals and all patients gave written informed consent.
Pretreatment evaluation included medical history, physical
examination, full blood counts with differential and platelets,
chemistry profile, chest radiography and abdominal computerized
tomography (CT) or ultrasound.
Of the 19 patients included in the study, 11 were men. Median
age was 61 years (range 48—86). Nine patients had CLL (two Binet
stage B, seven stage C), seven NHL-A (six stage IV, one stage III)
and three M. Eight were previously treated (one splenectomy, three
chemotherapy and 4, both). Previous chemotherapy consisted in
chlorambucil + prednisone in three patients and various combina-
tion regimen in four patients (details given in Table 1). Six patients
with CLL, 4 with NHL-A and 1 with M were untreated.
Treatment (Table 2)
Cladribine was supplied by the Swiss Group for Cancer Clinical
Research (SAKK) as a 0.1% solution of 1 mg ml—1 pyrogen-free
cladribine in sterile 0.9% sodium chloride. Cyclophosphamide and
prednisone were purchased from commercial sources. Cladribine
0.1 mg kg—1 per day was given subcutaneously for three consecu-
tive days with 500 mg m—2 i.v. cyclophosphamide on day 1 and
oral prednisone 40 mg m—2 day—1 on days 1—5. Courses were given
every 28 days. In the absence of WHO grade 4 haematological
toxicity and grade 3 non-haematological toxicity during courses 1
and 2, cladribine could be increased to 4 days for courses 3 and 4,
and up to a maximum of 5 days during courses 5 and 6. Patients
and treating physicians were allowed to stop CCP at any time.
Patients attended the clinic once weekly, with a full blood count
and other tests carried out as appropriate. On day 29, if leucocytes
were < 3 ´ 109 l—1 or neutrophils < 1 ´ 109 l—1 or thrombocytes
< 100 ´ 109 l—1, the treatment was delayed for 1 week. In case of no
recovery of these counts, the treatment was stopped unless low
counts were clearly related to the lymphoid malignancy. A maximum
of six courses of chemotherapy was planned. No restriction were
made on radiation therapy. Irradiated red blood cells or platelets were
given whenever indicated (Zulian et al, 1995). Prophylactic antibi-
otics and haematopoietic growth factors were not used.
Side-effects were considered from day 1 of the first course until
4 weeks after the end of the last course. Complications were
recorded as any events occurring later than one month after CCP
until the most recent follow-up.
Response criteria
Complete response (CR) was defined as the absence of active
disease on physical examination, chest radiography and abdominal
CT scan or ultrasound, peripheral blood count, bone marrow biopsy
and/or aspirate as well as protein electrophoresis. Partial response
(PR) was defined as a reduction of > 50% of all measurable disease
lasting for > 1 month. Anything else was qualified as no response
or progressive disease. Relapse was defined as an increase in serum
monoclonal protein by at least 25% in the case of M and reappear-
ance of adenopathy or lymphocytosis > 5 ´ 109 1—1 in the case of
NHL-A and CLL respectively.
Response was assessed after each cycle and after the third course
of CCP at known sites of disease. Response duration was calculated
from the first day of the response assessment. In the case of CR, no
further therapy was administered and, in the case of PR, CCP was
continued up to a maximum of six courses. patients whose disease
progressed during CCP could be switched to another treatment.
Follow-up was performed every month for the first trimester
after therapy, then every 3 months for 18 months, and thereafter
every 6 months until disease progression. Clinical examination
was done on each occasion together with full blood counts and
chemistry. Other tests were requested based on clinical grounds.
Survival was calculated from day 1 of the treatment according to
Kaplan and Meier (1958).
RESULTS
Dose modification
A total of 80 courses of CCP were administered. One patient
received only one 3-day course and declined further treatment.
Three patients received two courses, four patients received three
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Table 1 Patients’ characteristics
Age [median (range)] 61 years (48–86)
Sex (Male/female) 11/8
Previous treatment
None 11
Splenectomy 5
One year CLB-P 1
Four months CLB-P 1
Four months CLB-P, then 16 months
IFN + P 1
Six courses of CVP 1
One course of CVP + HDS 1
Six courses of CHOP 1
One course of CHOP, then six courses
of PACE 1
Diagnosis
CLL 9
NHL-A 7
M3
CLL, chronic lymphocytic leukaemia; NHL-A, non-Hodgkin’s lymphoma CLL-
like; M, macroglobulinaemia; CLB-P, chlorambucil, prednisone; IFN,
interferon alpha; CVP, cyclophosphamide, vincristine, prednisone; HDS, high-
dose steroids; CHOP, cyclophosphamide, doxorubicin, vincristine,
prednisone; PACE, procarbazine, cytarabine, etoposide, cisplatin.
Table 2 CCP combination (every 28 days)
Day
1 2345
Cladribine mg kg–1 s.c. 0.1 0.1 0.1 (0.1)a (0.1)a
Cyclophosphamide mg m–2 i.v. 500
Prednisone mg m–2 p.o. 40 40 40 40 40
aIn the case of < WHO grade 4 haematological toxicity and of < WHO grade 3
non-haematological toxicity.courses, two patients received four courses, one patient received
five courses and eight patients received the maximum of six
courses. There were 31 cycles of CCP with cladribine given for 3
days, 34 cycles with cladribine for 4 days and 15 cycles with
cladribine for 5 days.
Haematological toxicity during treatment (Table 3)
Myelosuppression was the most common side-effect, with 11
episodes of WHO grade 2 leucopenia (15% of cycles), eight grade
3 (10%), ten neutropenia grade 2 (13%), six grade 3 (4%), two
grade 4 (2.5%), four thrombocytopenia grade 2 (5%) and no other
grade 3 and 4 haematological toxicities.
Non-haematological toxicity during treatment (Table 3)
Nausea, vomiting, alopecia, mucositis, hepatic or renal failure and
neurological toxicity were non-existent. WHO grade 3 lung infection
occurred in one patient during the sixth course of CCP, requiring
hospitalization and parenteral antibiotics. WHO grade 2 lung infec-
tion occurred in one patient each during courses one, four, five and
six. Identification of the responsible pathogen was unsuccessful in
every case. There were no treatment-related deaths.
Haematological complications after treatment (Table 4)
There were eight WHO grade 2 haematological toxicities, four
grade 3 and one grade 4. Mean lymphocyte count 1 month after
the end of CCP was 735 G l—1 (median 759 G l—1, 350—6850);
1404 G l—1 after 3 months (median 1450 G l—1, 218—1700);
1565 G l—1 after 6 months (median 4000 G l—1, 100—70 870) and
2549 G l—1 after 9 months (median 6800 G l—1, 351—72 944).
Non-haematological complications after treatment
(Table 4)
There were 15 non-haematological complications, seven WHO
grade 2, four grade 3, two grade 4 and one non-gradable deep vein
thrombosis. Among these patients, one developed reversible adult
respiratory distress syndrome as a result of pneumococcaemia 13
months after the end of CCP. One patient died as the result of septi-
caemia due to Streptococcus pneumoniae 17 months after the end
of CCP.
Response
One patient was not assessable for response because he declined
further treatment on day 3 of the first course. Eighteen patients are
thus evaluable for response. After three courses, one patient
achieved CR and 15 achieved PR for an overall response rate of
88%. One pretreated CLL patient progressed and one untreated
NHL had no response. Three patients in PR after three courses
further responded to achieve CR after six courses. Overall CR rate
is thus 22% and 12 patients achieved PR for an unchanged overall
response rate of 88%. CR was obtained in two patients with
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Table 3 WHO overall toxicity on treatment
Days of 2CDA Number of cycles Course WBC Neutrophils Platelets Infections
G2 G3 G2 G3 G4 G2 G2 G3
31 9 1 11 2 1 1 a
39
49 2 13 1 4 1
32
41 1 3 32 4 2 1 1 b
52
31
48 4 21 1 1 1 b
52
43
56 5 11 1
43
55 6 31 1 1 1 a 1a
Total 80 80 11 8 10 6 2 4 4 1
aNon-viral infection. bHerpes (1 HSV2, 1 zoster).
Table 4 Major haematological and non-haematological toxicities during the
follow-up after the completion of treatment
Grade 2 Grade 3 Grade 4 Others
All toxicities 15 8 2 1
Anaemia 1 1 1
Thrombopenia 1 1
Leucopenia 3 2
Neutropenia 3
Bacterial infection 4 1 + 1a
Herpes 4
Candidosis 1
Diarrhoea 1
Pulmonary 1a
Deep venous thrombosis 1
Neurological toxicity 1
aSame patient.untreated CLL, one with previously treated CLL and one with
previously treated NHL-A. PR was obtained in three patients with
M, two patients with previously treated CLL, three with previ-
ously untreated CLL, three with untreated NHL and two with
pretreated NHL-A. Four patients received 30 Gy involved fields
radiation therapy in CR or in PR.
Relapses, progressions and survival
Eleven patients have relapsed, including four patients in CR, and
six have progressed from PR. After a minimum follow-up of 20
months, median duration of CR is 12 months and median duration
of PR is 15 months. Nine relapsing patients received further treat-
ment, four with purine analogues, two with prednisone and chlor-
ambucil, one with cyclophosphamide, two with radiotherapy and
two had a splenectomy. Overall survival is 68% at 3 years (95%
confidence interval, 36—85%). Six patients have died with PD.
DISCUSSION
Alkylating agents such as cyclophosphamide and chlorambucil
with or without the association of prednisone are considered the
standard cytotoxic treatment of CLL, NHL-A and M. Despite
remission rates as high as 70%, no cure is expected and the median
survival of 7 years does not make this treatment optimal. In addi-
tion, aggressive combination chemotherapy has not improved the
outlook for the majority of patients (French Cooperative Group on
Chronic Lymphocytic Leukemia, 1986).
In the present study of a mixed group of patients, we have shown
the feasibility of combining the purine analogue cladribine with the
standard treatment of cyclophosphamide and prednisone. In contrast
to other studies using cladribine in association with either chloram-
bucil or mitoxantrone (Tefferi et al, 1994; Saven et al, 1996), the
infection rate of our CCP combination was acceptable. This may
indeed be attributable to selection bias as over 50% of the patients
were previously untreated and could have better tolerated the
treatment. Another explanation is the difference in the doses of
cladribine that were given. In our study, cladribine was administered
for 3 days during the first course as opposed to 7 days in the other
studies. Furthermore, a maximum of 5 days was allowed, resulting
in a lower total dose for the patients completing the whole treatment.
The first three courses of the CCP combination were associated
with moderate myelosuppression and few infections. The total
amount of cladribine at that point of the treatment was relatively
low because patients received a maximum of 4 days of cladribine
during the first three courses. This is the most likely explanation
for the absence of detrimental toxicity. In addition, the majority of
responses were already achieved by that time and some patients
stopped their treatment. This is perhaps an indication that patients
responding quickly to CCP should be spared additional courses in
order to avoid potential cumulative toxicity.
Significant neutropenia or thrombocytopenia occurred only in
those patients continuing on the protocol to receive the maximum
of 5 days of cladribine. All patients eventually recovered from
toxicity, and no treatment-related death occurred. The overall
remission rate was not modified by additional courses of CCP, but
two patients in PR converted into CR indicating the continuous
activity of this combination in some cases. However, no attempt to
further escalate cladribine to the maximum tolerated dose was
contemplated in the present study.
Overall, the CCP combination was subjectively well tolerated
and could always be given in the outpatient facilities. Only one
hospitalization was necessary while the patient was on treatment.
We thus consider CCP to be cost-effective.
During the follow-up after CCP, two major life-threatening
bacterial infectious complications occurred, confirming a sustained
immunosuppression (Seymour et al, 1994; Cheson, 1995). This
should further point out our difficulties in selecting a treatment
after exposure to purine analogues and the need for alternatives.
On the basis of these observations, the combination of
cladribine at 0.1 mg kg—1 per day for 3 days with standard dose of
cyclophosphamide and prednisone appears safe in this small group
of patients. It remains to be seen whether under certain circum-
stances, such as perhaps in selected untreated patients, cladribine
could be administered for longer together with the same combina-
tion of cyclophosphamide and prednisone, and this is presently
under study. A further step would then require the randomized
comparison of adding cladribine to the combination of cylo-
phosphamide and prednisone.
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